NCT03139578

Brief Summary

This will be a 2 period one-day, double-masked, randomized, repeated measures, non-dispensing, cross-over study where the main purpose of this study is to compare the performance of a new daily disposable silicone hydrogel lens with that of an existing similar lens.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 28, 2017

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

May 2, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 4, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 22, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 22, 2017

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

December 11, 2018

Completed
Last Updated

February 1, 2019

Status Verified

January 1, 2019

Enrollment Period

6 months

First QC Date

May 2, 2017

Results QC Date

October 18, 2018

Last Update Submit

January 11, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Overall Fit Acceptance

    Overall lens fit acceptance was assessed by the investigator based on lens fitting characteristics and graded on a scale of 0 to 5, where 0=should not be worn and 5=perfect fit. The score ranges from 0 to 5, where higher scores indicate better fitting. The number of eye for each Grade was reported.

    30-45 minutes after lens settling

  • Lens Power Requirement

    The lens power requirements (aka sphere requirements) for each lens type was calculated by summing the lens power and the spherical over-refraction. Then the difference of lens power requirement between the Test and Control lenses was calculated (Test-Control).

    30-45 minutes after lens settling

Secondary Outcomes (5)

  • Subjective Comfort at Lens Insertion

    Immediately upon lens insertion

  • Subjective Comfort After Lens Settling

    30-45 minutes after lens settling

  • Subjective Vision Quality

    30-45 minutes after lens settling

  • Subjective Handling

    Immediately upon lens insertion

  • Monocular High Contrast Visual Acuity (VA)

    30-45 minutes after lens settling

Study Arms (4)

C 8.5\C 9.0\T 8.5\T 9.0

EXPERIMENTAL

Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.

Device: Test 8.5BCDevice: Test 9.0BCDevice: Control 8.5BCDevice: Control 9.0BC

C 9.0\C 8.5\T 9.0\T 8.5

EXPERIMENTAL

Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.

Device: Test 8.5BCDevice: Test 9.0BCDevice: Control 8.5BCDevice: Control 9.0BC

T 8.5\T 9.0\C 8.5\C 9.0

EXPERIMENTAL

Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.

Device: Test 8.5BCDevice: Test 9.0BCDevice: Control 8.5BCDevice: Control 9.0BC

T 9.0\T 8.5\C 9.0\C 8.5

EXPERIMENTAL

Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.

Device: Test 8.5BCDevice: Test 9.0BCDevice: Control 8.5BCDevice: Control 9.0BC

Interventions

senofilcon A contact lenses with 8.5 base curve

C 8.5\C 9.0\T 8.5\T 9.0C 9.0\C 8.5\T 9.0\T 8.5T 8.5\T 9.0\C 8.5\C 9.0T 9.0\T 8.5\C 9.0\C 8.5

senofilcon A contact lenses with 9.0 base curve

C 8.5\C 9.0\T 8.5\T 9.0C 9.0\C 8.5\T 9.0\T 8.5T 8.5\T 9.0\C 8.5\C 9.0T 9.0\T 8.5\C 9.0\C 8.5

narafilcon A contact lenses with 8.5 base curve

C 8.5\C 9.0\T 8.5\T 9.0C 9.0\C 8.5\T 9.0\T 8.5T 8.5\T 9.0\C 8.5\C 9.0T 9.0\T 8.5\C 9.0\C 8.5

narafilcon A contact lenses with 9.0 base curve

C 8.5\C 9.0\T 8.5\T 9.0C 9.0\C 8.5\T 9.0\T 8.5T 8.5\T 9.0\C 8.5\C 9.0T 9.0\T 8.5\C 9.0\C 8.5

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:
  • The subject must read and sign the Informed Consent form.
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Healthy adult males or females aged 18-55 years.
  • The subject's spherical contact lens requirement in the range +2.00 D to +4.00 D or -1.00 D to -6.00 D.
  • The subject's refractive cylinder must be ≤1.00 D in each eye.
  • The subject must have visual acuity best correctable to 6/9 (20/30) or better for each eye.
  • The subject is a current soft contact lens wearer (defined as a minimum of 6 hours of DW per day, at least 5 days per week, for a minimum of 1 month prior to the study).
  • The subject must have normal eyes (i.e., no ocular medications or infections of any type).

You may not qualify if:

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • Currently pregnant or lactating
  • Any systemic disease (e.g., Sjögren's Syndrome),allergies, infectious disease (e.g., hepatitis,tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
  • Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear.
  • Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
  • Extended wear contact lens correction.
  • Any current use of ocular medication.
  • Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.)
  • Any greater than Grade 2 slit lamp findings (e.g., oedema, corneal neovascularisation, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale or any other ocular abnormality that may contraindicate contact lens wear.
  • Any contact lens-related history or signs of a corneal inflammatory event, or any other ocular abnormality that would contraindicate contact lens wear.
  • Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrolment.
  • Employee, relative or friends of employees of any ophthalmic company, or investigational clinic (e.g., Investigator, Coordinator, Technician).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Aston University Optometry and Vision Science

Birmingham, United Kingdom

Location

Visioncare Research

Farnham, United Kingdom

Location

Results Point of Contact

Title
Anna Sulley BSc MCOptom FAAO
Organization
Johnson & Johnson Vision

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Both the investigator and the subjects are masked to the identity of the study lenses. Lenses were over-labelled and coded to mask the lens foil. Over-labelling was carried out by the study sponsor following specific SOPs (see ICH GCP guidelines Section 5.13).
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Contra-lateral Assignment
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 2, 2017

First Posted

May 4, 2017

Study Start

April 28, 2017

Primary Completion

October 22, 2017

Study Completion

October 22, 2017

Last Updated

February 1, 2019

Results First Posted

December 11, 2018

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations